Our results suggest that MKI67 and RACGAP1 could serve as promising biomarkers for detecting and predicting HCC caused by HBV/HCV via lactylation, opening a new direction for immune-targeted therapies. This evidence concerns the gene RACGAP1 and hepatocellular carcinoma.